Welcome. If you're a registered user, please log-in. If not, please sign-up.

       CPD Accredited

Your Course Leader
Course Reviews
"An excellent course which answered a lot of questions and concerns"
Responsible Analyst
"Excellent course and content. Trainer was superb. Best course I have attended"
R&D Manager, Biozyme Labs
Course features:


What are the expectations for heterogeneity in biotechnology products?


discussion of ongoing resources for biotechnology analytical CMC issues


...of all relevant regulatory, technical and wuality elements necessary to assure successful design


...from each phase of development will be illustrated.

CMC Analytical, Comparability and Stability Studies for Biotechnology and Biosimilar Products Training Course

Key Topics Include...

Biotechnology CMC Regulatory Requirements

Biotechnology Product Specifications; Comparability and Stability Issues

Biotechnology Analytical Methodology

Implementation of Biotechnology Laboratory Tests

Discussion of Ongoing Resources for Biotechnology Analytical CMC Issues

Course Objectives

To provide attendees with a clear, concise, but comprehensive overview of all relevant regulatory, technical and quality elements necessary to assure successful design, implementation and documentation of the required CMC analytical and stability studies for biotechnology products, including emerging biosimilar products. Key deliverables from each phase of development will be illustrated. Current ‘hot-button’ CMC analytical and stability issues will be presented, and strategies for preventing (or remediating) gaps will be presented.

Attendees will be given a CD containing a complete set of all regulatory documents and industry white papers currently applicable to biotechnology product analytical CMC requirements that covers the entire product development lifecycle.

Media Partners


Dates and Venues

08 Oct 2014 - 09 Oct 2014

Radisson Blu Edwardian Grafton

Performance and Knowledge Objectives

Attendees will be given a comprehensive overview of the phase-specific requirements for CMC analytical characterization, comparability, release and stability of biotechnology products from the pre-clinical phase through clinical trials to commercialisation and post-approval. Analytical considerations for a wide variety of biopharmaceuticals will be discussed, including monoclonal antibodies, therapeutic proteins, gene therapy, vaccines, and complex products (eg antibody drug conjugates). Details will be presented on establishing and maintaining product reference standards, designing successful comparability tests (including specifics for biosimilar studies), setting meaningful product specifications, conducting
forced degradation studies, tech transfer and bridging changes in analytical methods and generating effective stability protocols. Critical elements of laboratory quality practices that significantly impact the reliability of test data from R&D through cGMP will be illustrated.

Why you should attend

  • Create compliant stability protocols
  • Ensure EU and FDA regulatory compliance
  • Identify specifications for release

Download Latest Information Now

(updated 26 November 2014)

Latest Updates

BioProcess Special Report - Recommendations for Cell Banks Used in GXP Assays

Download here:http://www.pti-global.co.uk/event/stabilitybiotech/download/?id=10458


BioProcess Technical: Stability Considerations for Biopharmaceuticals, Part 1

Download here:http://www.pti-global.co.uk/event/stabilitybiotech/download/?id=10459

Follow us on Twitter


Connect with the PTI faculty! PTI is a global pharmaceutical training company with over 60 interctive courses focusing on Regulatory Affairs, R&D, Clinical, Business Strategy, Fine Chemicals, Biopharmaceuticals, Manufacturing, Medical Devices and Agrochemicals 

Other Events That Will Interest You

Analysing Bioassays and Immunoassays

1-2 December 2014 and 23-24 February 2015
Radisson Blu Edwardian Grafton

Comparability for Biologics

01 Dec 2014 - 02 Dec 2014